ArticleAsian Pacific journal of cancer prevention : APJCP2026
The Prognostic and Predictive Value of METTL3 in Metastatic Colorectal Cancer.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide, and its incidence continues to rise. The prognosis remains poor, especially for patients with metastatic disease. Methyltransferase-like 3 (METTL3) is the primary catalytic enzyme in the N6-methyladenosine (m6A) methyltransferase system. METTL3 plays a dual role, acting as either an oncogene or a tumor suppressor depending on the cancer type. It also plays a significant role in the response to treatment. However, its specific function in CRC remains unclear.
methodsA prospective cohort of sixty patients with metastatic colorectal cancer (mCRC) was enrolled at the South Egypt Cancer Institute (SECI). METTL3 expression was evaluated using immunohistochemistry (IHC). This study aimed to investigate METTL3 expression in CRC and its association with clinicopathological features and clinical outcomes in patients treated with oxaliplatin (OX)- and 5-fluorouracil (5-FU)-containing regimens.
resultsOur findings revealed that elevated METTL3 expression correlated with increased synchronous metastasis and a greater number of metastatic sites. In addition, elevated METTL3 was associated with increased lymphovascular invasion, perineural invasion, a non-brisk immune response, and greater tumor depth. Notably, right-sided tumors exhibited significantly higher METTL3 expression compared to those on the left side and in the rectum. Finally, METTL3 overexpression was associated with a lower response rate to OXA-based therapy, as well as shorter progression-free survival (PFS) and overall survival (OS), all with p < 0.05.
conclusionMETTL3 may serve as both a prognostic and predictive biomarker in colorectal cancer (CRC).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.